Popular Keywords

Antimicrobial resistance

Bacterial infections

Cross Infection

Eye Infections

Focal Infection

Fungal infections

Journal of Infectious Diseases, 2025, Volume 11, Issue 1, Pages: 1-16

Booster with Intranasal Vaccine Candidate Mambisa Activates the Expression of Tissue Resident Memory T Cell Markers.

Correspondence to Author: Daniel Palenzuela Gardón1 ,Diogenes Quintana Vazquez1, Hamlet Camacho Rodriguez1, Dania Vazque Blomquist1Jorge Aguiar Santiago1,Heryslina Izquierdo Reinoso1, Chabeli Rodriguez Ibarra1, Maité Delgado Espina1, Anabel Alvarez Acosta1,Alberto Cintado Benitez1, Karen Cobas Acosta1, Iris Valdez Prado1, Gilda Lemos Pérez1, Isela María García Tamayo1, Ingrid Rodriguez Alonso1, Julio Cesar Aguilar1, Damian Mainet Gonzalez1, Amanda Visal Fernandez1, Rubén Amaya Izquierdo1,Diosladia Urquiza Noa1, Pedro Puente Pérez1, Gerardo Guillen Nieto1

1. Center for Genetic Engineering and Biotechnology, Havana, Cuba.

DOI: 10.52338/joid.2025.4900

Abstract:

The study evaluates the efficacy of the nasal booster vaccine candidate Mambisa in the activation of tissue-resident memory T cells (TRM), that are essential in mucosal immunity against respiratory infections such as COVID-19. Mambisa, developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba, combines the RBD protein of SARS-CoV-2 and the HBcAg protein of hepatitis B, and is administered nasally. The preclinical study in mice showed that the nasal administration of Mambisa significantly increased the expression of CD69, and CD103 (TRM markers) in the lungs, while increased FOXP3 expression was also observed. Foxp3 is essential for the development and function of Treg cells, and can influence the activation and regulation of TRM cells. These results suggest that the combination of RBD and HBcAg induces an effective local immune response, with a synergistic effect that enhances TRM cell activation in tissues. Furthermore, mice immunized with Mambisa showed higher RBD-specific IgG antibody titers and increased neutralizing activity against the virus, compared to formulations with only RBD or HBcAg. In a study with nasal samples from 48 COVID-19 convalescent individuals receiving a booster shot with either Mambisa or intramuscular vaccine Abdala significant increases in the expression of genes associated with TRM (CD69, CD103) and effector immune responses (INFG, GZMB, CXCL10) were detected in the Mambisa group, indicating a local activation in the intranasal mucosa. In contrast, there were no significant differences in these markers in the Abdala group. TRM cells, residing in tissues such as the respiratory tract, act as a first line of defense, blocking viral replication and reducing transmission. The Mambisa formulation, by activating these markers, could enhance mucosal immunity, which is crucial in preventing emerging infections and variants. Moreover, the use of HBcAg as an adjuvant improves the RBD antigen presentation, enhancing specific T-cell and antibody responses. In summary, these results suggest that Mambisa is a promising candidate for inducing durable local immunity against SARS-CoV-2, with the potential to reduce transmission and mitigate future outbreaks.

Citation:

Dr. Daniel Palenzuela Gardón, Booster with Intranasal Vaccine Candidate Mambisa Activates the Expression of Tissue Resident Memory T Cell Markers. Journal of Infectious Diseases 2025.

Journal Info

  • Journal Name:Journal of Infectious Diseases
  • Impact Factor: 1.7
  • ISSN: 2831-8064
  • DOI: 10.52338/joid
  • Short Name: JOID
  • Acceptance rate: 55%
  • Volume: (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days
  • Crossref indexed journal
  • Publons indexed journal
  • Pubmed-indexed journal
  • International Scientific Indexing (ISI)-indexed journal
  • Eurasian Scientific Journal Index (ESJI) index journal
  • Semantic Scholar indexed journal
  • Cosmos indexed journal

OUR PUBLICATION BENEFITS

  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility